BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Lilly  ICOS  Limited  submitted  on  28  June  2001  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for CIALIS, 
through  the  centralised procedure.  After agreement  by  the  CPMP on  29  March  2001, this  medicinal 
product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC)  2309/93  of  
22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Prof. Fernando de Andres-Trelles 
Co-Rapporteur: 
Prof. Beatriz Lima 
Scientific Advice: 
The applicant did not seek scientific advice at the CPMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 17 July 2001. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 24 October 
2001. The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 1 
October 2001. 
During  the  meeting  on  13-15  November  2001  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 15 November 2001. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
13 December 2001. 
An Inspection of the Batch Release Site was not requested. 
The  Rapporteur  and  Co-Rapporteur  circulated  the  response  Assessment  Report  on  the 
company’s responses to the List of Questions to all CPMP members on 8 February 2002. 
During  the  CPMP  meeting  on  19-21  February  2002,  the  List  of  Outstanding  Issues  to  be 
addressed in writing and during an oral explanation was discussed and agreed by the CPMP. 
The company submitted the responses to the List of Outstanding Issues on 23 May 2002. 
The  Rapporteur  and  Co-Rapporteur  circulated  the  Joint  Assessment  Report  on  the  company’s 
written responses to the List of Outstanding Issues to all CPMP members on 18 June 2002. 
During  the  CPMP  meeting  on  25-27  June  2002,  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP. 
During the meeting on 23-25 July 2002 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation for CIALIS on 25 July 2002. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 12 November 2002. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
